Xencor (XNCR) Current Deferred Revenue (2013 - 2024)
Xencor (XNCR) posted quarterly Current Deferred Revenue of $36.5 million for Q2 2024, up 361.67% year-over-year from $7.9 million in Q3 2023, and up 6.99% quarter-over-quarter from $34.1 million in Q1 2024.
Analysis
Xencor (XNCR) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Xencor (XNCR) has reported Current Deferred Revenue for 12 consecutive years, with $36.5 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Current Deferred Revenue rose 361.67% year-over-year to $36.5 million; the TTM figure through Jun 2024 stood at $36.5 million (up 361.67% YoY), while the FY2022 annual figure was $30.3 million, down 18.71% from the prior year.
- Current Deferred Revenue grew to $36.5 million in Q2 2024 per XNCR's latest filing, from $34.1 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $92.6 million in Q4 2020 and bottomed at $7.9 million in Q2 2023.
- Historically, Current Deferred Revenue has averaged $37.0 million across 5 years, with a median of $35.3 million in 2022.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue sank 77.62% — and 2024, when it surged 361.67%.
- Xencor's Current Deferred Revenue stood at $92.6 million in 2020, then slumped by 59.72% to $37.3 million in 2021, then declined by 18.71% to $30.3 million in 2022, then tumbled by 69.58% to $9.2 million in 2023, then surged by 295.49% to $36.5 million in 2024.
- Business Quant data shows XNCR's Current Deferred Revenue at $36.5 million in Q2 2024, $34.1 million in Q1 2024, and $9.2 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 36.47 Mn |
| Mar 31, 2024 | 34.09 Mn |
| Sep 30, 2023 | 9.22 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 30.10 Mn |
| Dec 31, 2022 | 30.32 Mn |
| Sep 30, 2022 | 35.20 Mn |
| Jun 30, 2022 | 35.30 Mn |
| Mar 31, 2022 | 35.50 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 13.00 Mn |
| Jun 30, 2021 | 19.20 Mn |
| Mar 31, 2021 | 77.80 Mn |
| Dec 31, 2020 | 92.62 Mn |
| Sep 30, 2020 | 43.80 Mn |
| Jun 30, 2020 | 44.70 Mn |
| Mar 31, 2020 | 46.20 Mn |
| Dec 31, 2019 | 47.10 Mn |
| Sep 30, 2019 | 48.20 Mn |
| Jun 30, 2019 | 48.80 Mn |